Products
- Design
- Prescriptive Information
- Stent Size Matrix
- Clinical Data
- Directions for Use
- Patient Guide
- Reference Documents
TAXUS® Liberté®
Paclitaxel-eluting Coronary Stent System
Proven Performance and the TAXUS Family Clinical Program
The safety and efficacy of paclitaxel and the Translute™ Polymer have been tested and proven extensively in robust pre-clinical, clinical and real-world applications.
Unique, multifuntional anti-restenotic effect of paclitaxel
- Stabilizes microtubules to inhibit smooth muscle cell migration and proliferation
- Unlike other anti-restenonic agents, paclitaxel is not dependent on blocking a specific pathway and helps inhibit cell migration and proliferation regardless of the cellular signaling process or pathway
Stable, durable and reliable Translute Polymer
- Vascular compatible and biocompatible
- Provides consistent and controlled dose release of paclitaxel
TAXUS clinical program built upon the proven performance of paclitaxel
Trust Your Own Experience
The TAXUS® Stent family of products is built on long-term clinical outcomes and the proven performance of paclitaxel. Look to Boston Scientific's TAXUS Drug-Eluting Stent family, implanted in over four million patients worldwide, for proven drug-eluting stent performance.
